KB003-004: A 28 week study to evaluate the safety, tolerability and efficacy of a monthly  IV medication on lung function. It is said to act to reduce inflammation in the lungs in patients with asthma that is inadequately controlled by corticosteroids.

Recruiting now!

20120141: A 28 week study to Evaluate the Safety and Efficacy of an sub-cutaneous injection in those whose asthma symptoms are not controlled by the medications they are currently taking.

Recruiting soon! 

MEA115575: A 36 week study of Mepolizumab medication administered monthly via SC injection as an adjunctive therapy to reduce steroid use in patients with asthma.

Recruiting closed

MEA115588: A 44 week study to evaluate the efficacy and safety of Mepolizumab medication administered monthly either through IV or subcutaneous infusion. It is said to reduce inflammation in the lungs of patients with asthma, hoping to reduce the frequency of asthma exacerbations.

Recruiting closed

C8072/3082 - A 54 week study to learn about the efficacy of a monthly IV study medication on the frequency of asthma exacerbations and lung function. This medication is said to reduce inflammation in the lungs of patients with asthma. This study also offers patients the chance to participate in an open label extension program at the conclusion of the study.

Recruiting closed

MEA115666: An open label long term safety study of Mepolizumab medication administered monthly via subcutaneous infusion in asthmatics who participated in a previous trial.

Recruiting closed

GB27862: A phase III randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication.

Recruiting closed

MEA112997 – To test the effectiveness novel therapy on people with severe asthma.

AC-060A202: A new oral medication to reduce the inflammation in the lungs of people with asthma.